AB-1001
Experimental gene therapy
From Wikipedia, the free encyclopedia
AB-1001 is an experimental gene therapy developed for Huntington's disease. It is intended to increase the production of the CYP46A1 enzyme and cholesterol levels in the brain.[1][2]